Abstract
Similarly to other chemicals such as alcohol and solvents, drugs can injure the liver. A body of evidence suggests that mechanisms for drug induced liver injury (DILI) may follow a three-step cascade of events: drugs or their metabolites cause cell stress directly or through reactive oxygen species (ROS) during drug oxidation via cytochrome P450, impair mitochondrial functions, trigger immune reactions, and impair mitochondrial functions that would initiate apoptosis or necrosis leading to cell death. Clinically, toxicity DILI commonly refers to the idiosyncratic toxicity that occurs at therapeutic doses, affects a few susceptible individuals, and is not predictable. Conversely, intrinsic toxicity is dose dependent and thus predictable in individuals given an overdose of certain drugs such as acetaminophen. The diagnosis of DILI is based on timing of the events and the exclusion of alternative causes, and both require a quantitative scoring causality assessment method (CAM) such as RUCAM (Roussel Uclaf Causality Assessment Method), resulting in causality levels of highly probable, probable, possible, unlikely or excluded. For DILI characterization, only cases with a highly probable or probable causality grading should be used. Beside the product information, DILI databases and review articles should be consulted to help identify the offending drugs. Cessation of the suspected drug and symptomatic treatment commonly lead to a favorable outcome. N-acetylcysteine is the best treatment to prevent aggravation of DILI due to overdosed acetaminophen. In rare instances, DILI progresses in few days or weeks to acute liver failure requiring liver transplantation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Teschke R. Alcoholic steatohepatitis (ASH) and acute alcoholic hepatitis (AH): cascade of events, clinical features, and pharmacotherapy options. Exp Opin Pharmacother. 2018;19:779–93. https://doi.org/10.1080/14656566.2018.1465929.
Teschke R. Liver injury by carbon tetrachloride intoxication in 16 patients treated with forced ventilation to accelerate toxin removal via the lungs: a clinical report. Toxics. 2018;6:25. https://doi.org/10.3390/toxics6020025.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17:14. https://doi.org/10.3390/ijms17010014.
Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17:224. https://doi.org/10.3390/ijms17020224.
Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;39:561–75. https://doi.org/10.1007/s40264-016-0427-8.
Teschke R, Andrade R. Editorial: Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–3. https://doi.org/10.1053/j.gastro.2015.04.027.
Teschke R, Danan G. Review: drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018;84:1467–77.
Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf. 2018;41(8):735–43.
Teschke R, Danan G. Causality assessment methods in drug-induced liver injury. In: Chen M, Will Y, editors. Drug-induced liver toxicity (Chapter 27). James Kang Y, Casey D.C. Methods in pharmacology and toxicology. Springer protocols. Berlin: Springer Nature; 2018. p. 555–94. https://doi.org/10.1007/978-1-4939-7677-5_27.
Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;28:131–42. https://doi.org/10.14218/JCTH.2015.00052.
Iorga A, Dara L, Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int J Mol Sci. 2017;18:1018. Special issue. Molecular research on drug induced liver injury, guest editors R. Teschke and G. Danan.
Teschke R, Schulze J, Eickhoff A, Danan G. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Int J Mol Sci. 2017;18:803. https://doi.org/10.3390/ijms18040803. Special issue: Molecular research on drug induced liver injury.
Aithal GP, Grove JI. Genome-wide association studies in drug-induced liver injury: step change in understanding the pathogenesis. Semin Liver Dis. 2015;35:421–31.
McEuen K, Borlak J, Tong W, Chen M. Drug lipophilicity and extent of metabolism are culprits of drug-induced liver injury. Int J Mol Sci. 2017;18:1335.
Teschke R, Danan G. Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425–38. https://doi.org/10.1080/17425255.2017.1252749.
Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, Garbe E. Drug-induced liver injury: results from the hospital-based Berlin case-control surveillance study. Br J Clin Pharmacol. 2014;79:988–99.
Rathi C, Pipaliya N, Patel R, Ingle M, Phadke A, Sawant P. Drug induced liver injury at a tertiary hospital in India: Etiology, clinical features and predictors of mortality. Ann Hepatol. 2017;16:442–50. with commentary: Teschke R, Danan G. (eds). Prospective Indian study of DILI with confirmed causality using the Roussel Uclaf Causality Assessment Method (RUCAM): a report of excellence. Ann Hepatol 2017;16:324–25
Zhu Y, Niu M, Chen J, Zou ZS, Ma ZJ, Liu SH, Wang RL, He TT, Song HB, Wang ZX, Pu SB, Ma X, Wang LF, Bai ZF, Zhao YL, Li YG, Wang JB, Xiao XB. Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol. 2016;31:1476–82. https://doi.org/10.1111/jgh.13323.
Shahbaz O, Mahajan S, Lewis JH. Highlights of drug- and herb-induced liver injury in the literature from 2016: how best to translate new information into clinical practice? Exp Opin Drug Metab Tox. 2017;13:935–51. Available at: https://doi.org/10.1080/17425255.2017.1362391. Accessed July 1, 2018.
Teschke R. Commentary Drug- and herb-induced liver injury in 2016 with highly appreciated critical comments: related or not, that is the question. Clin Diagn Pathol. 2018;2(1):1–2. https://doi.org/10.15761/CDP.1000122.
Further Reading
Lu RJ, Zhang Y, Tang FL, Zheng ZW, Fan ZD, Zhu SM, Qian XF, Liu NN. Clinical characteristics of drug-induced liver injury and related risk factors. Exp Ther Med. 2016;12:2606–16.
Teschke R, Danan G. Editorial: Molecular research on drug induced liver injury. Int J Mol Sci. 2018;19:216. https://doi.org/10.3390/ijms19010216.
Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, Hu P, Hu XQ, Jia JD, Lai RT, Li DL, Liu JX, Lu LG, Ma SW, Ma X, Nan YM, Ren H, Shen T, Wang H, Wang JY, Wang TL, Wang XJ, Wei L, Xi Q, Xi W, Yang CQ, Yang DL, Yu YY, Zeng MD, Zhang L, Zhao XY, Zhuang H. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221–41. https://doi.org/10.1007/s12072-017-9793-2.
Related Links/Journals/Book
Teschke R, Andrade RJ. Special issue “Drug, herb, and dietary supplement hepatotoxicity”. Int J Mol Sci. 2016;17(9):1488. https://doi.org/10.3390/ijms17091488. Available at: http://www.mdpi.com/journal/ijms/special_issues/Hepatotoxicity. Last accessed July 1, 2018
Chen M, Will Y. Drug-induced liver toxicity. In: James Kang Y, Casey DC, editors. Methods in pharmacology and toxicology. Springer protocols. Berlin: Springer Nature; 2018. p. 555–94. https://doi.org/10.1007/978-1-4939-7677-5_27.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Self Study
Self Study
1.1 Questions
-
1.
Which statement is true?
-
(a)
RUCAM is the worldwide most commonly used causality assessment method to establish or dismiss the diagnosis of DILI.
-
(b)
Pathogenesis of idiosyncratic DILI is best studied with animal models.
-
(c)
Idiosyncratic DILI is not foreseeable and not preventable.
-
(d)
Patients with idiosyncratic DILI may profit from a variety of antidotes.
-
(a)
-
2.
Which statement/statements is/are true?
-
(a)
For the diagnosis of DILI, many alternative causes have to be excluded, since previous DILI cases often were not DILI but had to be attributed to other causes.
-
(b)
To describe the liver injury signature, a liver histology is required.
-
(c)
RUCAM represents an objective, quantitative diagnostic algorithm that uses defined key elements with individual scores.
-
(a)
1.2 Answers
-
1.
Which statement is true?
-
(a)
CORRECT: The worldwide preferred method is RUCAM, which is highly appreciated by regulatory agencies, large clinical centers, pharmaceutical manufacturers and authors of DILI case reports. RUCAM received an update in 2016, and this updated version should be used for future DILI cases.
-
(b)
Human idiosyncratic DILI is not reproducible in animal models, which are therefore not suitable for characterizing this toxic liver disease in humans.
-
(c)
CORRECT: Since idiosyncratic DILI is not predictable, patients under a drug therapy should be advised to carefully watch out for possible clinical signs
-
(d)
such as dark-colored urine, itching, jaundice, and abdominal pain.
-
(e)
No antidotes are available for idiosyncratic DILI, N-Acetylcysteine is an antidote only available for intrinsic DILI by overdosed acetaminophen.
-
(a)
-
2.
Which statement/statements is/are true?
-
(a)
CORRECT: Alternative causes are a problem in DILI cases and can be found by using RUCAM for general case evaluation and specific causality assessment.
-
(b)
DILI signature is based on serum activities of ALT and ALP rather than on liver histology obtained through invasive liver biopsy. ALT and ALP values clearly define DILI signature as hepatocellular liver injury or as cholestatic/mixed liver injury.
-
(c)
CORRECT: RUCAM is the preferred tool to assess causality of suspected DILI cases and cannot be replaced by any global introspection approach, which is, by definition, a subjective tool, lacking definition, transparency, and scoring system, and may lead to questionable results and conclusions.
-
(a)
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Teschke, R., Danan, G. (2020). Drug Induced Liver Injury: Mechanisms, Diagnosis, and Clinical Management. In: Radu-Ionita, F., Pyrsopoulos, N., Jinga, M., Tintoiu, I., Sun, Z., Bontas, E. (eds) Liver Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-24432-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-24432-3_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24431-6
Online ISBN: 978-3-030-24432-3
eBook Packages: MedicineMedicine (R0)